# A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

> **NCT01156571** · PHASE3 · COMPLETED · sponsor: **The Medicines Company** · enrollment: 11145 (actual)

## Conditions studied

- Atherosclerosis
- Percutaneous Coronary Intervention
- Acute Coronary Syndrome

## Interventions

- **DRUG:** cangrelor P2Y12 (platelet) inhibitor
- **DRUG:** Clopidogrel - 300 or 600 mg (study arm)
- **DRUG:** Clopidogrel 600 mg post cangrelor

## Key facts

- **NCT ID:** NCT01156571
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 11145 (ACTUAL)
- **Last updated:** 2014-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01156571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01156571, "A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01156571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*